SLW Institute

SLW Institute

Looking for educational content on intellectual property? The Schwegman firm has developed the SLW Institute, aimed to deliver educational and training content in a variety of ways for you to advance your IP knowledge.

Blog

PATENTS4LIFE

02/19/2010

Patents4Life

Sustained release fluvastatin formulations – The UK Court of Appeal opinion in Activis UK Limited v Novartis AG [2010] EWCA Civ 82

END OF AN ERA – "SWISS-FORM" CLAIMS ARE OUT

Claims to "New Uses of Old Compounds" – The Noose Tightens

Views of the EPO Enlarged Appeal Board in Treatment by surgery/MEDI-PHYSICS G 0001/07

PTO Biotech/Chem/Pharma Customer Partnership Meeting Announced

ANOTHER "HAIL MARY" CLAIM BITES THE DUST

PTO "POINT SYSTEM" DISTRIBUTED

Novelty and Obviousness In An Empirical Research Field – The Decision of the UK Court of Appeal in Dr Reddy’s Laboratories v Eli Lilly

Neutrokine-α litigation – On a different record from that before the EPO Appeal Board, the UK Court of Appeal finds different facts with a different result

BIO Joins Stakeholders in Expressing Concerns with Efforts to Restrict Gene Patenting

SACGHS Final Report on Gene Patents – Taking a Machete to the IP Thicket

Schwegman Lundberg & Woessner

Schwegman Lundberg & Woessner

Filter Resources

Resources By Type

Resources By Topic

Sustained release fluvastatin formulations – The UK Court of Appeal opinion in Activis UK Limited v Novartis AG [2010] EWCA Civ 82

END OF AN ERA – "SWISS-FORM" CLAIMS ARE OUT

Claims to "New Uses of Old Compounds" – The Noose Tightens

Views of the EPO Enlarged Appeal Board in Treatment by surgery/MEDI-PHYSICS G 0001/07

PTO Biotech/Chem/Pharma Customer Partnership Meeting Announced

ANOTHER "HAIL MARY" CLAIM BITES THE DUST

PTO "POINT SYSTEM" DISTRIBUTED

Novelty and Obviousness In An Empirical Research Field – The Decision of the UK Court of Appeal in Dr Reddy’s Laboratories v Eli Lilly

Neutrokine-α litigation – On a different record from that before the EPO Appeal Board, the UK Court of Appeal finds different facts with a different result

BIO Joins Stakeholders in Expressing Concerns with Efforts to Restrict Gene Patenting

SACGHS Final Report on Gene Patents – Taking a Machete to the IP Thicket

Court Decision in China Recognizes Novelty in Dosage Limitations in Swiss-Form Claims

Schwegman Lundberg & Woessner

SLW Institute

Filter Resources

Resources By Type

Resources By Topic

Subscribe

Sustained release fluvastatin formulations – The UK Court of Appeal opinion in Activis UK Limited v Novartis AG [2010] EWCA Civ 82

END OF AN ERA – "SWISS-FORM" CLAIMS ARE OUT

Claims to "New Uses of Old Compounds" – The Noose Tightens

Views of the EPO Enlarged Appeal Board in Treatment by surgery/MEDI-PHYSICS G 0001/07

PTO Biotech/Chem/Pharma Customer Partnership Meeting Announced

ANOTHER "HAIL MARY" CLAIM BITES THE DUST

PTO "POINT SYSTEM" DISTRIBUTED

Novelty and Obviousness In An Empirical Research Field – The Decision of the UK Court of Appeal in Dr Reddy’s Laboratories v Eli Lilly

Neutrokine-α litigation – On a different record from that before the EPO Appeal Board, the UK Court of Appeal finds different facts with a different result

BIO Joins Stakeholders in Expressing Concerns with Efforts to Restrict Gene Patenting

SACGHS Final Report on Gene Patents – Taking a Machete to the IP Thicket

Court Decision in China Recognizes Novelty in Dosage Limitations in Swiss-Form Claims